Drug-drug interactions: Proof of relevance (Part I)

Journal of Psychiatric Practice

Volumn 11, Issue 2, 2005, Pages 116-122

  Preskorn, Sheldon H ^a,b  

^a UNIVERSITY OF KANSAS SCHOOL OF MEDICINE WICHITA   (United States)

^b University of Montreal   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; CELECOXIB; CLOZAPINE; CYTOCHROME P450; CYTOCHROME P450 1A2; CYTOCHROME P450 2D6; CYTOCHROME P450 3A; FLUOXETINE; FLUVOXAMINE; KETOCONAZOLE; MONOAMINE OXIDASE INHIBITOR; NEFAZODONE; PAROXETINE; PSYCHOTROPIC AGENT; RISPERIDONE; ROFECOXIB; SEROTONIN UPTAKE INHIBITOR; TERFENADINE;

DELIRIUM; DISEASE EXACERBATION; DRUG METABOLISM; DRUG SAFETY; HEART ARRHYTHMIA; HUMAN; MALIGNANT HYPERTENSION; MENTAL DISEASE; NEUROLEPTIC MALIGNANT SYNDROME; QT PROLONGATION; REVIEW; RISK ASSESSMENT; SEIZURE; SEROTONIN SYNDROME; SIDE EFFECT; SUDDEN DEATH; TORSADE DES POINTES; WITHDRAWAL SYNDROME;

ANTI-BACTERIAL AGENTS; ANTIFUNGAL AGENTS; ANTIPSYCHOTIC AGENTS; CYCLOPHILINS; DRUG INTERACTIONS; DRUG THERAPY; ERYTHROMYCIN; HUMANS; LONG QT SYNDROME; MENTAL DISORDERS; METRONIDAZOLE;

EID: 16344365275     PISSN: 15274160     EISSN: None     Source Type: Journal    
DOI: 10.1097/00131746-200503000-00006     Document Type: Review

References (42)

1. Preskorn SH, Silkey B, Shah R, et al. Complexity of medication use in the Veterans Affairs healthcare system: Part I: Outpatient use in relation to age and number of prescribers. J Psychiatr Pract 2005;11:5-15.
2. Silkey B, Preskorn SH, Golbeck A, et al. Complexity of medication use in the Veterans Affairs healthcare system: Part II. Antidepressant use among younger and older outpatients. J Psychiatr Pract 2005;11:16-26.
3. Preskorn SH. Multiple medication use in patients seen in the Veterans Affairs healthcare system: So what? J Psychiatr Pract 2005;11:46-50.
4. U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Health Statistics. Health, United States 2004. Hyattsville, MD, 2004 (Can be accessed at www.cdc.gov/nchs/hus.htm).
5. Preskorn SH. The case studies section. Series of columns published in the Journal of Psychiatric Practice (www.preskorn.com/column1.html).
6. Preskorn SH. Classification of neuropsychiatric medications by principal mechanism of action: A meaningful way to anticipate pharmacodynamically mediated drug interactions. J Psychiatr Pract 2003;9:376-84.
7. Preskorn SH. Classification of neuropsychiatric medications by principal mechanism of action: A meaningful way to anticipate pharmacodynamically mediated drug interactions (Part II). J Psychiatr Pract 2004;10:177-81.
8. Preskorn SH. Reproducibility of the in vivo effect of the selective serotonin reuptake inhibitors on the in vivo function of cytochrome P450 2D6: An update (part I). J Psychiatr Pract 2003;9:150-8.
9. Preskorn SH. Reproducibility of the in vivo effect of the selective serotonin reuptake inhibitors on the in vivo function of cytochrome P450 2D6: An update (part II). J Psychiatr Pract 2003;9:228-36.
10. Preskorn SH. The rationale for and clinical implications of dose-response curves. Series of columns published in the Journal of Practical Psychiatry and Behavioral Health (www.preskorn.com/column3.html).
11. Preskorn SH, Baker B. Fatality associated with combined fluoxetine-amitriptyline therapy. JAMA 1997;277:1682.
12. Ferslew KE, Hagardorn AN, Harlan GC, et al. A fatal drug interaction between clozapine and fluoxetine. J Forensic Sci 1998;43:1082-5.
13. Preskorn SH. Fatal drug-drug interactions as a differential consideration in apparent suicides. J Psychiatr Pract 2002;8:233-8.
14. Spigset O, Hedenmalm K, Dahl ML, et al. Seizures and myoclonus associated with antidepressant treatment: Assessment of potential risk factors, including CYP2D6 and CYP2C19 polymorphisms, and treatment with CYP2D6 inhibitors. Acta Psychiatr Scand 1997;96:379-84.
15. Ahmed I, Dagincourt PG, Miller LG, et al. Possible interaction between fluoxetine and pimozide causing sinus bradycardia. Can J Psychiatry 1993;38:62-3.
16. Azaz-Livshits TL, Danenberg HD. Tachycardia, orthostatic hypotension and profound weakness due to concomitant use of fluoxetine and nifedipine. Pharmacopsychiatry 1997;30:274-5.
17. Beasley CM, Jr., Masica DN, Heiligenstein JH, et al. Possible monoamine oxidase inhibitor-serotonin uptake inhibitor interaction: Fluoxetine clinical data and preclinical findings. J Clin Psychopharmacol 1993;13:312-20.
18. Otte W, Birkenhager TK, van den Broek WW. Fatal interaction between tranylcypromine and imipramine. Eur Psychiatry 2003;18:264-5.
19. Preskorn SH. "I don't see 'em." Journal of Practical Psychiatry and Behavioral Health 1997;3:302-7.
20. Reeves RR, Mack JE, Beddingfield JJ. Neurotoxic syndrome associated with risperidone and fluvoxamine. Ann Pharmacother 2002;36:440-3.
21. Stanford BJ, Stanford SC. Postoperative delirium indicating an adverse drug interaction involving the selective serotonin reuptake inhibitor, paroxetine? J Psychopharmacol 1999;13:313-7.
22. Robinson RF, Nahata MC, Olshefski RS. Syncope associated with concurrent amitriptyline and fluconazole therapy. Ann Pharmacother 2000;34:1406-9.
23. Moskowitz H, Burns M. The effects on performance of two antidepressants, alone and in combination with diazepam. Prog Neuropsychopharmacol Biol Psychiatry 1988;12:783-92.
24. Spina E, Avenoso A, Scordo MG, et al. Inhibition of risperidone metabolism by fluoxetine in patients with schizophrenia: A clinically relevant pharmacokinetic drug interaction. J Clin Psychopharmacol 2002;22:419-23.
25. Sperber AD. Toxic interaction between fluvoxamine and sustained release theophylline in an 11-year-old boy. Drug Saf 1991;6:460-2.
26. de Leon J, Susce MT, Pan RM, et al. The CYP2D6 poor metabolizer phenotype may be associated with risperidone adverse drug reactions and discontinuation. J Clin Psychiatry 2005;66:15-27.
27. Ludgate J, Keating J, O'Dwyer R, et al. An improvement in cognitive function following polypharmacy reduction in a group of epileptic patients. Acta Neurol Scand 1985;71:448-52.
28. Preskorn SH. Do you believe in magic? Journal of Practical Psychiatry and Behavioral Health 1997;3:99-103.
29. Preskorn SH. A message from Titanic. Journal of Practical Psychiatry and Behavioral Health 1998;4:236-42.
30. Malek-Ahmadi P, Allen SA. Paroxetine-molindone interaction (case report). J Clin Psychiatry 1995;56:82-3.
31. Johne A, Schmider J, Brockmoller J, et al. Decreased plasma levels of amitriptyline and its metabolites on comedication with an extract from St. John's wort (Hypericum perforatum). J Clin Psychopharmacol 2002;22:46-54.
32. Bertschy G, Baumann PA, Eap CB, et al. Probable metabolic interaction between methadone and fluvoxamine in addict patients. Ther Drug Monit 1994;16:42-5.
33. Preskorn SH. Comparison of the tolerability of bupropion, fluoxetine, imipramine, nefazodone, paroxetine, sertraline, and venlafaxine. J Clin Psychiatry 1995;56(Suppl 6):12-21.
34. De Ponti F, Poluzzi E, Montanaro N. Organising evidence on QT prolongation and occurrence of torsades de pointes with non-antiarrhythmic drugs: A call for consensus. Eur J Clin Pharmacol 2001;57:185-209.
35. Tamargo J. Drug-induced torsade de pointes: From molecular biology to bedside. Jpn J Pharmacol 2000;83:1-19.
36. Health Science Alerts. Product safety alert: Nefazodone and liver failure. Can be accessed at www.hsa.gov.sg/docs/safetyalert_nefazodone_Feb03.pdf
37. Richard IH, Kurlan R, Tanner C, et al. Serotonin syndrome and the combined use of deprenyl and an antidepressant in Parkinson's disease. Neurology 1997;48:1070-7.
38. Shad MU, Preskorn SH. Antidepressants. In: Levy RH, Thummel KE, Trager WF, et al., eds. Metabolic drug interactions. Philadelphia: Lippincott, Williams & Wilkins 2000:563-77.
39. Clozapine (Clozaril) package insert. Physicians' Desk Reference, 49th edition. Montvale, NJ: Medical Economics Data Production; 1995:596-9.
40. Wetzel H, Anghelescu I, Szegedi A, et al.. Pharmacokinetic interactions of clozapine with selective serotonin reuptake inhibitors: Differential effects of fluvoxamine and paroxetine in a prospective study. J Clin Psychopharmacol 1998;18:2-9.
41. Ray WA, Murray KT, Meredith S, et al. Oral erythromycin and the risk of sudden death from cardiac causes. N Engl J Med 2004;351:1089-96.
42. Marder SR, Meibach RC. Risperidone in the treatment of schizophrenia. Am J Psychiatry 1994;151:825-35.